Kingsview Wealth Management LLC Sells 3,908 Shares of Novo Nordisk A/S (NYSE:NVO)

Kingsview Wealth Management LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 15.4% in the third quarter, Holdings Channel reports. The firm owned 21,392 shares of the company’s stock after selling 3,908 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,547,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Natixis Advisors LLC boosted its position in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. lifted its holdings in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares during the period. Private Wealth Partners LLC increased its stake in Novo Nordisk A/S by 155.1% during the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after purchasing an additional 20,188 shares in the last quarter. Finally, Buckingham Capital Management Inc. acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $3,874,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 2.4 %

NYSE NVO opened at $105.06 on Monday. The company has a market cap of $471.46 billion, a PE ratio of 34.00, a PEG ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The stock has a 50 day moving average of $115.48 and a 200-day moving average of $128.81. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.